TransCode Therapeutics Inc (RNAZ)

[dinogreeves]

Then you must be the Saudi Price.

[tapioca]

What a board,,,, 😆

[MetaMonster]

?Allaha ?uakbar?,

[Xunefox]

Well that seems like a false information violation.

[MetaMonster]

Saudi prince will kill the shorts by buying out the float

[tapioca]

Guess peeps are desperate for something that will move this north, but it's not happenin'

[Money hunt]

Goodmorning dude!!! Rise and shine!!

[peterus]

idiot

[Money hunt]

News tomorrow morning dudes!!!

[tapioca]

Some volume today at least..

[Speculator gipsy]

When news comes this piece of shit company will collapse, management scammed all investors

[Speculator gipsy]

Management screwed all investors

[Speculator gipsy]

A hoax will always remain a hoax, it's a reversed piece of shit

[Speculator gipsy]

Yes last week and it collapses, this cancer hoax company shat on all investors

[Money hunt]

Any news hit the wires dudes!!!

[MetaMonster]

69 lovely close

[MetaMonster]

Nuclear bomb news is close

[Money hunt]

Load and hold for breakthrough news next week dude!!

[tapioca]

All sounds good but hasn’t moved the needle..

[Ms Labonte]

Junkie$$ not filling em bid$$ $weet$$$

[MetaMonster]

Uppercut way of knockout for the shorts $RNAZ recent 1/40 reverse and regained compliance, recently announced collaboration agreement with Debiopharm in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer, recent offering closed price at $1.22 per share

[MetaMonster]

The word is out on the streets piece of shit Kevin Tang is completely out of the stock so we don’t have to worry about him dumping anymore,

[tapioca]

Hurting the shorts would require heavy volume and a big spike, which could happen with the right news. Otherwise the shorts will wait in the shadows for the pps to move up a bit and then short it right back down. IMO We’ll see.

[MetaMonster]

Lets put the shorts in the corner and let them have it premarket

[MetaMonster]

Nice accumulation, what a day, golden move is next

[MetaMonster]

This spring is fully compressed it contains alot of potential energy, energy that can explode in an instance

[Speculator gipsy]

Burning it down, super thin to 1$

[Speculator gipsy]

1$ In sight

[Speculator gipsy]

Time to burn down the 69 wall

[tapioca]

Well, they’re not in trouble until it starts to run, if it ever does..

[Money hunt]

With shorts in trouble, Blue Skies the limit!!!!

[tapioca]

Steady accumulation…

[MetaMonster]

Route 66 Highway to Hell lmao

[MetaMonster]

Bulls stampede

[MetaMonster]

The devil is at play, but one thing is for sure short rats are shitting in their pants

[Ms Labonte]

Fill em bid$$$ $hort junkie$$$

[Ms Labonte]

$how me a $ign of life $weet$$$

[Ms Labonte]

$hort$ deserve to $cream $weet$$$ I love you$$$$

[Ms Labonte]

They dropped their pant$$$ It can $cream

[tapioca]

How the heck did this stock drop so far down from where it was …wow.

[Money hunt]

Shorts in big trouble dude!!! I smell burnt rubber!!! It’s a Breakthrough in the clinic TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
February 20 2024 - 08:00AM


Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported publication of United States Patent Application titled, “Nanoparticles and Template Directed RIG-I Agonist Precursor Compositions and Uses Thereof For Cancer Therapy“ (Pub. No.: US 2024/0042070 A1; Pub. Date: February 8, 2024).
The application describes compositions and methods to treat cancer using a novel class of immunotherapy inspired by the innate immunity of mammalian cells against microbes. This novel type of immunotherapy targets molecules called retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs). RLRs are key RNA sensors that can be activated for the treatment of cancer using synthetic RNAs that mimic viral infection, directing the immune response against cancer. There is no assurance that any patent will issue from this application.

TransCode’s RIG-I agonist precursor comprises single-stranded 5’-uncapped biphosphate or triphosphate oligonucleotides having a sequence complementary to an endogenous microRNA. The precursor may be carried by a nanoparticle such as TransCode’s TTX delivery technology and may include a radiolabel for imaging or therapy. It is designed to activate the immune system against tumor cells with high specificity potentially resulting in effective treatment of multiple primary, metastatic, and recurrent cancers. What is novel about TransCode’s approach is the capacity to recruit pattern recognition receptors (PRRs), such as RIG-I, in a tumor-selective manner which TransCode believes is critical for clinical applications.

“TransCode’s tumor-selective RIG-I agonists could enable this novel immunotherapy against cancer by triggering the immune system to attack the specific tumor while sparing healthy tissue,” commented Zdravka Medarova, Ph.D., Chief Science Officer at TransCode. “Further selectivity against cancer may be achievable by linking RIG-I agonists to TransCode’s TTX delivery platform. This linkage mechanism is currently being studied in a first-in-human microdose clinical trial with a radiolabeled version of TransCode’s lead therapeutic candidate, TTX-MC138. TTX-MC138 consists of an iron oxide nanocarrier conjugated to a nucleic acid specifically designed to inhibit the oncogenic RNA, microRNA-10b. Preliminary data indicate that following dosing, radioactivity accumulated in the region of the metastatic lesions, consistent with accumulation of TTX-MC138 in lesions observed in preclinical qualitative studies. Data analysis from the subject dosed in this trial is ongoing and will be included in the final trial report.”

[Ms Labonte]

Wake up $weet$$$ I miss you$$$$

[Ms Labonte]

I ove you $weet$$$ welcome to the party$$$$

[LowFloatLopes]

I’ve been seeing and hearing this stock pop up everywhere in the last week so I decided to join :)

[tapioca]

~~~

[Money hunt]

News just hit international wires TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
February 20 2024 - 08:00AM


Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported publication of United States Patent Application titled, “Nanoparticles and Template Directed RIG-I Agonist Precursor Compositions and Uses Thereof For Cancer Therapy“ (Pub. No.: US 2024/0042070 A1; Pub. Date: February 8, 2024).
The application describes compositions and methods to treat cancer using a novel class of immunotherapy inspired by the innate immunity of mammalian cells against microbes. This novel type of immunotherapy targets molecules called retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs). RLRs are key RNA sensors that can be activated for the treatment of cancer using synthetic RNAs that mimic viral infection, directing the immune response against cancer. There is no assurance that any patent will issue from this application.

TransCode’s RIG-I agonist precursor comprises single-stranded 5’-uncapped biphosphate or triphosphate oligonucleotides having a sequence complementary to an endogenous microRNA. The precursor may be carried by a nanoparticle such as TransCode’s TTX delivery technology and may include a radiolabel for imaging or therapy. It is designed to activate the immune system against tumor cells with high specificity potentially resulting in effective treatment of multiple primary, metastatic, and recurrent cancers. What is novel about TransCode’s approach is the capacity to recruit pattern recognition receptors (PRRs), such as RIG-I, in a tumor-selective manner which TransCode believes is critical for clinical applications.

“TransCode’s tumor-selective RIG-I agonists could enable this novel immunotherapy against cancer by triggering the immune system to attack the specific tumor while sparing healthy tissue,” commented Zdravka Medarova, Ph.D., Chief Science Officer at TransCode. “Further selectivity against cancer may be achievable by linking RIG-I agonists to TransCode’s TTX delivery platform. This linkage mechanism is currently being studied in a first-in-human microdose clinical trial with a radiolabeled version of TransCode’s lead therapeutic candidate, TTX-MC138. TTX-MC138 consists of an iron oxide nanocarrier conjugated to a nucleic acid specifically designed to inhibit the oncogenic RNA, microRNA-10b. Preliminary data indicate that following dosing, radioactivity accumulated in the region of the metastatic lesions, consistent with accumulation of TTX-MC138 in lesions observed in preclinical qualitative studies. Data analysis from the subject dosed in this trial is ongoing and will be included in the final trial report.”

[Money hunt]

Hell yes dude!!!

[MetaMonster]

Yes RNAZ Is a breakthrough in the clinic RNA-i technology It's the hail Mary of cancer research, Stock can hit record all time high of $5000

[Hercules1]

So this stock has presence on reddit?

[MetaMonster]

RNAZ Is the next HOLO $100